X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3191) 3191
Book Review (908) 908
Publication (277) 277
Book Chapter (24) 24
Conference Proceeding (20) 20
Newsletter (6) 6
Dissertation (2) 2
Magazine Article (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2896) 2896
humans (1886) 1886
animals (1529) 1529
male (1422) 1422
aldosterone (954) 954
female (918) 918
rats (841) 841
mineralocorticoid receptor antagonists - therapeutic use (733) 733
mineralocorticoid receptor (708) 708
spironolactone (655) 655
hypertension (567) 567
mineralocorticoid receptor antagonists - pharmacology (513) 513
spironolactone - pharmacology (500) 500
endocrinology & metabolism (498) 498
middle aged (475) 475
mineralocorticoid receptor antagonists - administration & dosage (447) 447
spironolactone - therapeutic use (444) 444
corticosteroids (443) 443
adult (440) 440
steroids (427) 427
spironolactone - analogs & derivatives (421) 421
receptors, mineralocorticoid - metabolism (407) 407
cardiac & cardiovascular systems (400) 400
neurosciences (400) 400
heart failure (395) 395
mineralocorticoid receptor antagonists (380) 380
heart failure - drug therapy (360) 360
aged (358) 358
pharmacology & pharmacy (352) 352
abridged index medicus (341) 341
spironolactone - administration & dosage (326) 326
eplerenone (325) 325
treatment outcome (320) 320
blood-pressure (302) 302
peripheral vascular disease (294) 294
mice (291) 291
blood pressure - drug effects (289) 289
rats, sprague-dawley (281) 281
brain (265) 265
physiology (262) 262
angiotensin-converting enzyme inhibitors - therapeutic use (250) 250
corticosterone (250) 250
heart-failure (249) 249
hypertension - drug therapy (246) 246
angiotensin-ii (244) 244
aldosterone - pharmacology (234) 234
mortality (229) 229
rats, wistar (229) 229
urology & nephrology (229) 229
stress (225) 225
mineralocorticoid receptor antagonists - adverse effects (222) 222
oxidative stress (221) 221
blood pressure (220) 220
drug therapy, combination (220) 220
time factors (215) 215
dose-response relationship, drug (213) 213
mineralocorticoids (213) 213
aldosterone - blood (211) 211
aldosterone - metabolism (206) 206
rodents (202) 202
research (200) 200
hypertension - physiopathology (196) 196
mineralocorticoid receptors (196) 196
analysis (194) 194
medicine & public health (193) 193
glucocorticoid receptor (192) 192
receptors, mineralocorticoid - physiology (187) 187
receptors, glucocorticoid - metabolism (185) 185
fibrosis (184) 184
drug therapy (183) 183
myocardial-infarction (181) 181
renin-angiotensin system - drug effects (179) 179
risk factors (179) 179
expression (178) 178
receptors, mineralocorticoid - genetics (177) 177
biochemistry & molecular biology (175) 175
physiological aspects (173) 173
glucocorticoids (170) 170
angiotensin (166) 166
care and treatment (162) 162
hippocampus (160) 160
aldosterone - physiology (159) 159
heart failure - physiopathology (158) 158
left-ventricular dysfunction (155) 155
disease models, animal (154) 154
double-blind method (153) 153
cardiology (150) 150
gene-expression (149) 149
adrenalectomy (148) 148
article (145) 145
inflammation (142) 142
cortisol (140) 140
spironolactone - adverse effects (134) 134
health aspects (132) 132
hormones (132) 132
diuretics - therapeutic use (123) 123
adrenergic beta-antagonists - therapeutic use (121) 121
heart (121) 121
medicine, general & internal (121) 121
antihypertensive agents - therapeutic use (120) 120
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3085) 3085
German (42) 42
French (17) 17
Japanese (15) 15
Russian (12) 12
Spanish (12) 12
Italian (6) 6
Danish (4) 4
Chinese (3) 3
Norwegian (3) 3
Polish (3) 3
Hungarian (2) 2
Bosnian (1) 1
Bulgarian (1) 1
Dutch (1) 1
Lithuanian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CURRENT PHARMACEUTICAL DESIGN, ISSN 1381-6128, 2018, Volume 24, Issue 46, pp. 5537 - 5541
Background: Minemlocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However,... 
MORTALITY | ALDOSTERONE ANTAGONISTS | FINERENONE | eplerenone | Mineralocorticoid receptor antagonist | hyperkalemia | HEART-FAILURE | adverse event | spironolactone | GITELMAN-SYNDROME | LEFT-VENTRICULAR DYSFUNCTION | PHARMACOKINETICS | GYNECOMASTIA | PHARMACOLOGY & PHARMACY | acute kidney injury
Journal Article
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2018, Volume 20, Issue 10, pp. 2399 - 2407
Aim: To determine whether non-steroidal mineralocorticoid receptor (MR) antagonists oppose metabolic syndrome-related end-organ, i.e. cardiac, damage.... 
drug development | cardiovascular disease | type 2 diabetes | diabetes complications | experimental pharmacology | animal pharmacology | CHRONIC HEART-FAILURE | OXIDATIVE STRESS | MYOCARDIAL-INFARCTION | ENDOTHELIAL DYSFUNCTION | CONTRACTILE DYSFUNCTION | DIASTOLIC DYSFUNCTION | FAILING DIABETIC HEART | LEFT-VENTRICULAR DYSFUNCTION | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | NITRIC-OXIDE | Mineralocorticoid Receptor Antagonists - administration & dosage | Drug Administration Schedule | Kidney Diseases - prevention & control | Naphthyridines - adverse effects | Cardiovascular Diseases - prevention & control | Ventricular Function, Left - drug effects | Mineralocorticoid Receptor Antagonists - adverse effects | Rats | Male | Metabolic Syndrome - drug therapy | Metabolic Syndrome - complications | Rats, Zucker | Heart Rate - drug effects | Cardiovascular Diseases - complications | Animals | Time Factors | Metabolic Syndrome - physiopathology | Hemodynamics - drug effects | Kidney Diseases - complications | Metabolic Syndrome - pathology | Oxidative Stress - drug effects | Nitric Oxide - metabolism | Naphthyridines - administration & dosage | Type 2 diabetes | Medicine, Experimental | Medical research | Nitric oxide | Steroids | Oxidative stress | Reactive oxygen species | Renal function | Echocardiography | Bioavailability | Metabolic syndrome | Heart rate | Nephropathy | Magnetic resonance imaging | Perfusion | Collagen | Blood pressure | Diabetes | Hemodynamics | Ventricle | Acute effects | Metabolic disorders | Proteinuria | Index Medicus
Journal Article
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 12/2009, Volume 20, Issue 12, pp. 2641 - 2650
Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the... 
PRONE HYPERTENSIVE-RATS | VASCULAR INJURY | CONTROLLED-TRIAL | CARDIOVASCULAR OUTCOMES | ALDOSTERONE ANTAGONISM | HEART-FAILURE | RENAL OUTCOMES | UROLOGY & NEPHROLOGY | BLOOD-PRESSURE CONTROL | CHRONIC KIDNEY-DISEASE | ANTIHYPERTENSIVE TREATMENT | Angiotensin II Type 1 Receptor Blockers - adverse effects | Spironolactone - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Diabetic Nephropathies - drug therapy | Hypertension - drug therapy | Male | Diabetic Nephropathies - physiopathology | Lisinopril - adverse effects | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Bicarbonates - blood | Blood Pressure - drug effects | Albuminuria - urine | Drug Therapy, Combination | Hypertension - urine | Spironolactone - adverse effects | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Lisinopril - administration & dosage | Diabetic Nephropathies - urine | Mineralocorticoid Receptor Antagonists - administration & dosage | Double-Blind Method | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Creatinine - urine | Hypertension - physiopathology | Albuminuria - drug therapy | Losartan - adverse effects | Potassium - blood | Renin-Angiotensin System - drug effects | Losartan - administration & dosage | Index Medicus | Clinical Research
Journal Article
Circulation: Heart Failure, ISSN 1941-3289, 2014, Volume 7, Issue 4, pp. 573 - 579
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 08/2015, Volume 761, pp. 226 - 234
The present study was designed to characterize the pharmacological profile of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist. In the... 
CS-3150 | Aldosterone | Urinary Na+/K+ ratio | Mineralocorticoid receptor antagonist | Urinary Na | ratio | TARGET | OXIDATIVE STRESS | DIABETIC-NEPHROPATHY | MESSENGER-RNA | PHARMACOKINETICS | SPIRONOLACTONE | INFLAMMATION | ALDOSTERONE BLOCKER | PHARMACOLOGY & PHARMACY | HYPERTENSION | EPLERENONE | Receptors, Mineralocorticoid - genetics | Urological Agents - pharmacology | Antihypertensive Agents - pharmacology | Pyrroles - pharmacokinetics | Receptors, Mineralocorticoid - metabolism | Humans | Transcriptional Activation - drug effects | Rats, Inbred WKY | Desoxycorticosterone Acetate | Male | Water-Electrolyte Balance - drug effects | Spironolactone - metabolism | Sulfones - pharmacology | Dose-Response Relationship, Drug | Receptors, Mineralocorticoid - drug effects | Aldosterone - metabolism | Spironolactone - pharmacology | Transfection | Sodium - urine | Pyrroles - administration & dosage | Hypertension - chemically induced | HEK293 Cells | Mineralocorticoid Receptor Antagonists - pharmacology | Hypertension - prevention & control | Female | Blood Pressure - drug effects | Radioligand Assay | Spironolactone - analogs & derivatives | Disease Models, Animal | Binding, Competitive | Mineralocorticoid Receptor Antagonists - administration & dosage | Rabbits | Administration, Oral | Aldosterone - pharmacology | Sulfones - pharmacokinetics | Rats, Sprague-Dawley | Hypertension - physiopathology | Adrenalectomy | Pyrroles - pharmacology | Animals | Potassium - urine | Protein Binding | Mineralocorticoid Receptor Antagonists - pharmacokinetics | Sulfones - administration & dosage | Hypertension | Hormones, Sex | Corticosteroids | Drug discovery | Spironolactone | Index Medicus
Journal Article
by Montalescot, Gilles and Pitt, Bertram and Lopez De Sa, Esteban and Hamm, Christian W and Flather, Marcus and Verheugt, Freek and Shi, Harry and Turgonyi, Eva and Orri, Miguel and Vincent, John and Zannad, Faiez and Noll, Georg and Weir, Robin and O'Neill, Blair and Böhm, Michael and Hillis, W. Stuart and Grieve, Andrew and Rouleau, Jean-Lucien and Gerasimos, Filippatos and Fitchett, David and Lepage, Serge and Madan, Minakshi and Sussex, Bruce and Tremblay, Gerald and Welsh, Robert and Wong, Graham and Hutyra, Martin and Kettner, Jiri and Ostadal, Petr and Spinar, Jindrich and Vojacek, Jan and Barboteu, Michel and Collet, Jean-Philippe and Coste, Pierre and Cottin, Yves and Ducos, Dominique and Galinier, Michel and Teiger, Emmanuel and Zemour, Gilles and Bauersachs, Johann and Hambrecht, Rainer and Hauf, Gerhard and Heuer, Hubertus and Mudra, Harald and Münzel, Thomas and Steiner, Stephan and Strasser, Ruth and Sydow, Karsten and Tschöpe, Carsten and Wachter, Rolf and Werner, Nikos and Alexopoulos, Dimitros and Babalis, Dimitrios and Pyrgakis, Vlassios and Dezsi, Csaba and Lupkovics, Geza and Polgar, Peter and Tomcsanyi, Janos and Herrman, J and Ten Berg, J.M and Gorny, Jerzy and Kubica, Jacek and Lewczuk, Jerzy and Zmuda, Witold and Hranai, Marian and Kovar, Frantisek and Margoczy, Roman and Micko, Karol and Sumbal, Jaroslav and Genover, Xavier Bosch and Ortiz, Antonio Fernandez and Sala, Miguel Fiol and Garcia, Cosme Garcia and Muñoz, Carlos Perez and Blas, Juan Ramon Rey and Soriano, Franciso Ridocci and Adamson, Dawn and Alamgir, Farqad and Chauhan, Anoop and Lip, Gregory and Martin, Thomas and McCann, Gerry and Newby, David and Smith, David and Reminder Invest and REMINDER Investigators and for the REMINDER Investigators
European Heart Journal, ISSN 0195-668X, 2014, Volume 35, Issue 34, pp. 2295 - 2302
Journal Article
Diabetes, ISSN 0012-1797, 01/2015, Volume 64, Issue 1, pp. 236 - 242
Journal Article